Adherence to treatment in patients with multiple myeloma and pain syndrome

Background. Treatment adherence is one of the key factors influencing the therapy outcome in patients with multiple myeloma complicated by pain syndrome.
Aim. To clarify the treatment adherence features in patients with multiple myeloma.
Materials and methods. The data of 61 patients with pain syndrome associated with bortezomib-induced polyneuropathy and oral mucositis were studied. Men – 17 (27.9 %), women – 44 (72.1 %). Median age – 52 (31–67) years. Assessment of pain syndrome and psychometric parameters of patients was performed in hospital before autologous hematopoietic stem cell transplantation (1st point), on the 8th (2nd point) and 100th (3rd point) days after transplantation. Validated algometric and psychometric methods were used.
Results. At each study point, patients with high adherence were grouped into 1st group, and patients with low adherence were grouped into 2nd group. At 1st point, statistically significant differences were noted between the groups in such indicators as quality of life / satisfaction and the degree of polyneuropathy. At the 2nd point, significant differences were found in the types of patient’s attitude toward illness: in the 1st group, adaptive types (harmonious, ergopathic) predominated, in the 2nd – maladaptive ones (anxious, neurasthenic, and sensitive). At 3rd point, a statistically significant difference was noted between the groups in the severity of mental disorders symptoms, the presence of which may be associated with decreased adherence to treatment, as well as the presence exclusively in the group with a low treatment adherence a maladaptive (egocentric) type of attitude toward illness.
Conclusion. Adherence to treatment in patients with multiple myeloma complicated by pain syndrome is a complex problem that requires a multidisciplinary team of specialists, which should include hematologists, algologists, and mental health specialists (psychiatrists, medical psychologists).

1. Zhuge L., Lin X., Fan Z. et al. Global, regional and national epidemiological trends of multiple myeloma from 1990 to 2021: a systematic analysis of the Global Burden of Disease study 2021. Front Public Health 2025;13(27):1527198. DOI: 10.3389/fpubh.2025.1527198

2. Rajkumar S.V. Multiple myeloma: 2024 update on diagnosis, riskstratification, and management. Am J Hematol 2024;99(9):1802–24. DOI: 10.1002/ajh.27422

3. Gackowski M., Jasińska-Stroschein M., Osmałek T., Waszyk-Nowaczyk M. Innovative approaches to enhance and measure medication adherence in chronic disease management: a review. Med Sci Monit 2024;30:e944605. DOI: 10.12659/MSM.944605

4. Guio J., Melo A., Saldarriaga M.M. et al. A novel digital educational strategy improves treatment adherence and quality of life in patients with multiple myeloma. J Cancer Educ 2024;39(1):50–7. DOI: 10.1007/s13187-023-02374-w

5. Amonoo H.L., Deary E.C., Wang A. et al. Medication adherence in patients with hematologic malignancies who are hematopoietic stem cell transplantation survivors: a qualitative study. Transplant Cell Ther 2023;29(10):620.e1–11. DOI: 10.1016/j.jtct.2023.07.019

6. Derakhshan A., Mansouri A., Jafarzadeh Kohneloo A., Hadjibabaie M. Adherence to immunosuppressants among adult patients after allogeneic hematopoietic stem-cell transplantation (allo-HSCT): a cross-sectional study. Int J Hematol Oncol Stem Cell Res 2022;17(4):231–9. DOI: 10.18502/ijhoscr.v17i4.13913

7. Visintini C., Mansutti I., Palese A. Medication adherence among allogeneic haematopoietic stem cell transplant recipients: a systematic review. Cancers (Basel) 2023;15(9):2452. DOI: 10.3390/cancers15092452

8. Visintini C., Lucchetta C., Venturini M. et al. Perspective on oral medication adherence among patients with acute graft-versus-host disease: a qualitative descriptive study. Support Care Cancer 2024;32(10):633. DOI: 10.1007/s00520-024-08825-4

9. Ice L.L., Bartoo G.T., McCullough K.B. et al. A prospective survey of outpatient medication adherence in adult allogeneic hematopoietic stem cell transplantation patients. Biol Blood Marrow Transplant 2020;26(9):1627–34. DOI: 10.1016/j.bbmt.2020.05.020

10. Belaiche S., Décaudin B., Caron A. et al. Medication nonadherence after allogeneic hematopoietic cell transplantation in adult and pediatric recipients: a cross-sectional study. Fundam Clin Pharmacol 2021;35(2):435–45. DOI: 10.1111/fcp.12593

11. Kolgaeva E.I., Drokov M.Yu., Vybornykh D.E. Treatment adherence in patients with blood system diseases and recipients of allogeneic organs and tissues. Onkogematologiya = Oncohematology 2023;18(1):132–41. (In Russ.). DOI: 10.17650/1818‑8346‑2023‑18‑1‑132‑141

12. Irugova E.Z., Mendeleeva L.P., Vybornykh D.E. et al. Bortezomibinduced peripheral neuropathy in patients with multiple myeloma: pain syndrome and psychopathological aspects. Onkogematologiya = Oncohematology 2025;20(1):154–64. (In Russ.). DOI: 10.17650/1818‑8346‑2025‑20‑1‑154-164

13. Chang X., Yao S., Wei J. et al. The validation and cross-cultural adaptation of the PainDETECT questionnaire in osteoarthritisrelated pain. J Orthop Surg Res 2025;20(1):94. DOI: 10.1186/s13018-025-05510-y

14. Lanfredini R., Cipriani L. The experience of pain and its ontological modelling from a philosophical point of view: phenomenological description and ontological revision of the McGill Pain Questionnaire. J Eval Clin Pract 2023;29(7):1211–21. DOI: 10.1111/jep.13879

15. Radchikova N.P., Adashinskaya G.A., Sanoyan T.R., Shupta A.A. Russian adaptation of the pain catastrophizing scale. Klinicheskaya i specialnaya psihologiya = Clinical Psychology and Special Education 2020;4(9):169–87. (In Russ.). DOI: 10.17759/cpse.2020090409

16. Hofmann A.B., Schmid H.M., Jabat M. et al. Utility and validity of the Brief Psychiatric Rating Scale (BPRS) as a transdiagnostic scale. Psychiatry Res 2022;314:114659. DOI: 10.1016/j.psychres.2022.114659

17. Snodgrass M.A., Bieu R.K., Schroeder R.W. Development of a symptom validity index for the Beck Anxiety Inventory. Clin Neuropsychol 2024;15:1–16. DOI: 10.1080/13854046.2024.2429162

18. Shura R.D., Schroeder R.W., Ord A.S. et al. Symptom validity indices for the Beck Depression Inventory – II: development and cross-validation. Clin Neuropsychol 2024;22:1–19. DOI: 10.1080/13854046.2024.2432058

19. Wasserman L.I., Iovlev B.V., Karpova E.B., Vuks A.Y. Psychological diagnosis of attitudes toward illness: physician manual. Saint Petersburg: NIPNI im. Bekhtereva, 2005. 33 p. (In Russ.).

20. Nikolaev N.A., Skirdenko Yu.P. Russian universal questionnaire for quantitative assessment of treatment adherence (QAP-25). Klinicheskaya farmakologiya i terapiya = Clinical Pharmacology and Therapeutics 2018;1(27):74–8. (In Russ.).

21. Rasskazova E.I. Evaluation of quality of life enjoyment and satisfaction: psychometric properties of a Russian-language measure. Psikhologiya. Zhurnal Vysshey shkoly ekonomiki = Psychology. Journal of Higher School of Economics 2012;4(9): 81–90. (In Russ.).

22. Irugova E.Z., Vybornykh D.E., Gemdzhian E.G. et al. Pain syndrome and mental disorders in patients with multiple myeloma and post-transplantation oral mucositis. Kremlevskaya meditsina. Klinicheskij vestnik = Kremlin Medicine Journal 2024;4:62–8. (In Russ.). DOI: 10.48612/cgma/5fbb-64pn-xxed

23. Foulon V., Schöffski P., Wolter P. Patient adherence to oral anticancer drugs: an emerging issue in modern oncology. Acta Clin Belg 2011;66(2):85–96. DOI: 10.2143/ACB.66.2.2062525

24. Bouwman L., Eeltink C.M., Visser O. et al. Prevalence and associated factors of medication non-adherence in hematological-oncological patients in their home situation. BMC Cancer 2017;17(1):739. DOI: 10.1186/s12885-017-3735-1

25. Hall A.E., Paul C., Bryant J. et al. To adhere or not to adhere: rates and reasons of medication adherence in hematological cancer patients. Crit Rev Oncol Hematol 2016;97:247–62. DOI: 10.1016/j.critrevonc.2015.08.025